FDA leaders Drs. Margaret Hamburg and Joshua Sharfstein should consider allowing patients access to cancer drugs that have proven effective in certain indications even if such uses have not been approved by the agency, writes Richard Epstein, a law professor at the University of Chicago and a senior fellow at Stanford University's Hoover Institution. The FDA can collaborate with the National Comprehensive Cancer Network, a group of 21 cancer centers, to offer cancer drugs that have gone through Phase I clinical trials so more patients can benefit from the treatments, Epstein writes.

Related Summaries